Sign up to save your podcasts
Or
Share NETWise Episode 44: Radiopharmaceutical Treatment – FAQs & Insights
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NETWise Episode 44: Radiopharmaceutical Treatment – FAQs & Insights
When it comes to PRRT (Peptide Receptor Radionuclide Therapy), patients often have big questions and concerns. In this episode, we dive into the most common questions surrounding PRRT and the broader field of radiopharmaceutical treatments for neuroendocrine cancer. This is an exciting field as there is much more research being done into radiopharmaceuticals for neuroendocrine cancer. Tune in as we break down key insights from doctors and researchers to help you better understand this important treatment option.
NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed.
Beth Chasen, MD, is a Professor, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Victor Fernandes, PHD is a researcher at the University of Wisconsin Madison and a medical physicist by training, I work with radiopharmaceutical therapies and with neuroendocrine tumor patients and patient data. Victor was awarded a research grant by NANETS funded through NETFRF that focuses on Modeling to predict the benefit of PRRT in NET patients.
Heather Jacene, MD, is a Clinical Director, Nuclear Medicine/PET-CT
Associate Program Director at Brigham and Women’s Joint Program in Nuclear Medicine. In addition, she is an Associate Professor of Radiology Harvard Medical School
Click here to download a transcript of this episode.
The post NETWise Episode 44: Radiopharmaceutical Treatment – FAQs & Insights appeared first on NETRF.
View all episodes
By Neuroendocrine Tumor Research Foundation (NETRF)
4.8
4545 ratings
When it comes to PRRT (Peptide Receptor Radionuclide Therapy), patients often have big questions and concerns. In this episode, we dive into the most common questions surrounding PRRT and the broader field of radiopharmaceutical treatments for neuroendocrine cancer. This is an exciting field as there is much more research being done into radiopharmaceuticals for neuroendocrine cancer. Tune in as we break down key insights from doctors and researchers to help you better understand this important treatment option.
NET specialists included in this episodeUse our episode infographics to get a visual picture of some of the things we have discussed.
Beth Chasen, MD, is a Professor, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Victor Fernandes, PHD is a researcher at the University of Wisconsin Madison and a medical physicist by training, I work with radiopharmaceutical therapies and with neuroendocrine tumor patients and patient data. Victor was awarded a research grant by NANETS funded through NETFRF that focuses on Modeling to predict the benefit of PRRT in NET patients.
Heather Jacene, MD, is a Clinical Director, Nuclear Medicine/PET-CT
Associate Program Director at Brigham and Women’s Joint Program in Nuclear Medicine. In addition, she is an Associate Professor of Radiology Harvard Medical School
Click here to download a transcript of this episode.
The post NETWise Episode 44: Radiopharmaceutical Treatment – FAQs & Insights appeared first on NETRF.
More shows like NETWise
View all
The Rachel Maddow Show
36,781 Listeners